293 related articles for article (PubMed ID: 33571964)
1. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
[TBL] [Abstract][Full Text] [Related]
2. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
3. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A; Moriguchi M; Seko Y; Ishikawa H; Yo T; Kimura H; Fujii H; Shima T; Mitsumoto Y; Ishiba H; Takashima H; Nagao Y; Jo M; Arai M; Hara T; Okajima A; Muramatsu A; Morita A; Yoshinami N; Nakajima T; Mitsuyoshi H; Umemura A; Nishikawa T; Yamaguchi K; Itoh Y
Anticancer Res; 2019 Sep; 39(9):5149-5156. PubMed ID: 31519627
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
5. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
11. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M;
Cancer Med; 2019 Jul; 8(8):3719-3728. PubMed ID: 31127698
[TBL] [Abstract][Full Text] [Related]
13. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
17. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
18. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
20. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
